By FitBizWeekly Staff
Canada has become the first G7 country to approve a generic version of semaglutide—the active ingredient in widely used GLP-1 drugs such as Ozempic—marking a significant development in one of the fastest-growing segments of the health and wellness market.
Health Canada recently authorized a generic injectable semaglutide from Dr. Reddy’s Laboratories, following a full review confirming safety, efficacy, and quality equivalence to the branded product. The approval comes as demand for GLP-1 medications continues to rise globally, driven by their use in both type 2 diabetes management and, increasingly, weight loss.
From a market perspective, the introduction of generics is expected to begin reshaping pricing dynamics. Generic medications in Canada can be significantly less expensive than branded versions—often 45% to 90% lower over time—although initial price reductions may be more modest until multiple competitors enter the market. Health Canada is currently reviewing several additional generic GLP-1 submissions, which could accelerate price compression in the coming months.
For operators across the fitness and wellness industry, the implications extend beyond healthcare. The rapid adoption of GLP-1 medications has already begun influencing member behavior, particularly around weight loss, body composition, and training needs. Increased accessibility through generics may further expand the population using these drugs—introducing new considerations around muscle preservation, strength training, and long-term lifestyle adherence.
At the same time, the regulatory approval remains specific to type 2 diabetes treatment, with weight management use continuing largely as an off-label application in Canada. This distinction may influence insurance coverage and patient access, particularly for individuals seeking GLP-1 therapies primarily for weight loss.
More broadly, Canada’s early move into generic GLP-1 availability positions the country as a potential test case for global markets. As patents expire at different times internationally, stakeholders—including operators, healthcare providers, and policymakers—will be watching closely to understand how increased competition impacts pricing, adoption, and long-term outcomes in this rapidly evolving category.



